The group's principle activities include discovery and development of breakthrough small molecule kinase inhibitors for a broad range of oncology/angiogenesis and autoimmune/allergic/inflammatory disease indications. The group also provides assay development, kinase inhibitor focused library, High-throughput Accelerated Lead Optimization (HALO) Platform, in-vivo disease models, and clinical/regulatory affairs. The group operates from United States.
